These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 27109624)
1. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype. Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624 [TBL] [Abstract][Full Text] [Related]
2. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Rabiner EA; Beaver J; Makwana A; Searle G; Long C; Nathan PJ; Newbould RD; Howard J; Miller SR; Bush MA; Hill S; Reiley R; Passchier J; Gunn RN; Matthews PM; Bullmore ET Mol Psychiatry; 2011 Aug; 16(8):826-35, 785. PubMed ID: 21502953 [TBL] [Abstract][Full Text] [Related]
5. The Novel μ-Opioid Receptor Antagonist GSK1521498 Decreases Both Alcohol Seeking and Drinking: Evidence from a New Preclinical Model of Alcohol Seeking. Giuliano C; Goodlett CR; Economidou D; García-Pardo MP; Belin D; Robbins TW; Bullmore ET; Everitt BJ Neuropsychopharmacology; 2015 Dec; 40(13):2981-92. PubMed ID: 26044906 [TBL] [Abstract][Full Text] [Related]
6. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine]. Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812 [TBL] [Abstract][Full Text] [Related]
7. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Ray LA; Hutchison KE Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272 [TBL] [Abstract][Full Text] [Related]
8. The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects. Ziauddeen H; Nathan PJ; Dodds C; Maltby K; Miller SR; Waterworth D; Song K; Warren L; Hosking L; Zucchetto M; Bush M; Johnson LV; Sarai B; Mogg K; Bradley BP; Richards DB; Fletcher PC; Bullmore ET J Clin Pharmacol; 2013 Oct; 53(10):1078-90. PubMed ID: 23934621 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating. Giuliano C; Robbins TW; Nathan PJ; Bullmore ET; Everitt BJ Neuropsychopharmacology; 2012 Nov; 37(12):2643-52. PubMed ID: 22805601 [TBL] [Abstract][Full Text] [Related]
10. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036 [TBL] [Abstract][Full Text] [Related]
11. The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours. Kelly E; Mundell SJ; Sava A; Roth AL; Felici A; Maltby K; Nathan PJ; Bullmore ET; Henderson G Psychopharmacology (Berl); 2015 Jan; 232(1):305-14. PubMed ID: 24973897 [TBL] [Abstract][Full Text] [Related]
12. Increased ethanol drinking in "humanized" mice expressing the mu opioid receptor A118G polymorphism are mediated through sex-specific mechanisms. Henderson-Redmond AN; Lowe TE; Tian XB; Morgan DJ Brain Res Bull; 2018 Apr; 138():12-19. PubMed ID: 28780411 [TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981 [TBL] [Abstract][Full Text] [Related]
14. Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people. Cambridge VC; Ziauddeen H; Nathan PJ; Subramaniam N; Dodds C; Chamberlain SR; Koch A; Maltby K; Skeggs AL; Napolitano A; Farooqi IS; Bullmore ET; Fletcher PC Biol Psychiatry; 2013 May; 73(9):887-94. PubMed ID: 23245760 [TBL] [Abstract][Full Text] [Related]
15. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. Kranzler HR; Armeli S; Covault J; Tennen H Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013 [TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial. Ray LA; Green R; Roche DJO; Bujarski S; Hartwell EE; Lim AC; Rohrbaugh T; Ghahremani D; Hutchison K; Miotto K Alcohol Clin Exp Res; 2018 Mar; 42(3):613-623. PubMed ID: 29265379 [TBL] [Abstract][Full Text] [Related]
17. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH; Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034 [TBL] [Abstract][Full Text] [Related]
18. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251 [TBL] [Abstract][Full Text] [Related]
19. Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects. Ziauddeen H; Chamberlain SR; Nathan PJ; Koch A; Maltby K; Bush M; Tao WX; Napolitano A; Skeggs AL; Brooke AC; Cheke L; Clayton NS; Sadaf Farooqi I; O'Rahilly S; Waterworth D; Song K; Hosking L; Richards DB; Fletcher PC; Bullmore ET Mol Psychiatry; 2013 Dec; 18(12):1287-93. PubMed ID: 23147384 [TBL] [Abstract][Full Text] [Related]
20. Increased mesolimbic cue-reactivity in carriers of the mu-opioid-receptor gene OPRM1 A118G polymorphism predicts drinking outcome: a functional imaging study in alcohol dependent subjects. Bach P; Vollsta Dt-Klein S; Kirsch M; Hoffmann S; Jorde A; Frank J; Charlet K; Beck A; Heinz A; Walter H; Sommer WH; Spanagel R; Rietschel M; Kiefer F Eur Neuropsychopharmacol; 2015 Aug; 25(8):1128-35. PubMed ID: 25937240 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]